+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 25Years - 65Years
All Genders
Healthy Volunteers
ID06996730

Double-Blind Study of Donanemab and RG6289 to Evaluate Treatment in PSEN1 E280A Mutation Carriers with Autosomal-Dominant Alzheimers Disease

Led by Banner Health · Updated on 2026-09-02

240

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of donanemab and RG6289, alone or in combination, in people who carry the PSEN1 E280A mutation, which causes autosomal-dominant Alzheimers disease. The trial is conducted in two parts. In the first part, mutation carriers receive donanemab and non-carriers receive a placebo, with treatments lasting up to 18 months. Amyloid PET scans are used to monitor brain amyloid levels at screening and during treatment. Participants may move to the second part based on amyloid clearance or after completing part one. In the second part, mutation carriers are randomly assigned to one of four groups donanemab alone, RG6289 alone, both drugs combined, or placebo, while non-carriers continue receiving placebo. Participants receive donanemab or placebo via intravenous infusion at specific intervals and take RG6289 or placebo as a daily oral tablet. This double-blind, double-dummy design continues for up to 18 months. The study lasts up to three years for each participant, excluding screening and follow-up. Participants undergo cognitive and functional assessments, amyloid PET imaging, and biomarker tests throughout the study to evaluate changes in brain amyloid and other measures of Alzheimers disease. The primary outcomes include changes in amyloid levels measured by PET scans at various time points. Safety and efficacy are closely monitored, with the study sponsored by Banner Health and including adults aged 25 to 65 years who meet specific genetic and cognitive criteria.

CONDITIONS

Brief Title

A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

Research Team

D

David Gordon, M.S.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here